



Title: MD

Academic Degree: Professor
Ophthalmology Department
Iran University of Medical Sciences Iran
Address: Rassoul Akram Hospital
Niayesh Street, Sattar-khan Street
Tehran
Iran

Work: ++98 21 66885511
Fax: ++98 21 66885511
Post box: 1445613131
E-mail: masoodnp@yahoo.com
Alternative: naseripour.m@iums.ac.ir

Masood Naseripour

Education

- **Doctor of Medicine** **1983-1989**
School of Medicine
Tabriz University of Medical Sciences
Tabriz, Iran
- **Ophthalmology** **1989-1992**
School of Medicine
Tabriz University of Medical Sciences
Tabriz, Iran
- **Vitreoretinal Surgery** **1993-1995**
School of Medicine
Iran University of Medical Sciences
Tehran, Iran
- **Ocular Oncology** **2000-2001**
Wills Eye Hospital
Thomas Jefferson University
Philadelphia, USA

Work Experience

- **Ophthalmologist/ Member of Faculty** 1995-2000
Ophthalmology Department
Kermanshah University of Medical Sciences
- **Head of Ophthalmology Department** 1996-1997
Kermanshah University of Medical Sciences
- **Deputy for Education and Research** 1997-2000
Kermanshah University of Medical Sciences
- **Secretary of Iranian Council for Graduate Medical Education** 2001- 2004
- **Ophthalmologist/ Member of Faculty** 2001-Present
Ophthalmology Department
Iran University of Medical Sciences
- **Head of Ophthalmology Department** 2005-2007
Iran University of Medical Sciences
- **Member of Board of Trustee** 2004-2008
Kermanshah University of Medical Sciences
- **Head of Eye Research Center** 2003-2010
Iran University of Medical Sciences
- **Director of Ophthalmology Department** 2011-2013
Iran University of Medical Sciences
- **Executive Director**
The 18th, 22nd, 23rd, 24th and 25th Annual Congress of the Iranian Society of
Ophthalmology
- **Dean of Medical School** 2014-2017
Iran University of Medical Sciences
- **Chancellor** 2017-2019
Iran University of Medical Sciences
- **Member of Iranian Board of Ophthalmology** 2014-Present
- **Head of Iranian Board of Ophthalmology** 2015-Present
- **Head of Eye Research Center** 2019-Present
Iran University of Medical Sciences

- **Head of Stem Cell and Regenerative Medicine Institute** 2019-Present
Iran University of Medical Sciences
- **Head of Stem Cell and Regenerative Medicine Research Center** 2019-Present
Iran University of Medical Sciences
- **Head of Ophthalmology Research Network** 2021-Present

Scientific Positions

- **Editorial Board** 1998-Present
The journal of "**Behbood**"
Kermanshah University of Medical Sciences
- **Scientific Reviewer** 1998-Present
The journal of "**Behbood**"
Kermanshah University of Medical Sciences
- **Professor, Director of Ocular Oncology Unit** 2001-Present
Eye Department, Rassoul Akram Hospital
Iran University of Medical Sciences
- **Scientific Member** 2001-Present
Iranian Retina Society
- **Scientific Reviewer** 2002-Present
The journal of "**BINA**"
Iranian Eye Bank journal
- **Scientific Reviewer** 2002-Present
The journal of "**Ir J Ophthalmology**"
Iranian Society of Ophthalmology
- **Editorial Board** 2005-Present
The journal of "**Ir J Ophthalmology**"
Iranian Society of Ophthalmology
- **Editorial Board** 2003-Present
The journal of "**Medical Education**"
Shahid Beheshti University of Medical Sciences
- **Scientific Reviewer** 2010-Present
The journal of "**Saudi Journal of Ophthalmology**"
Saudi Arabia

- **Scientific Reviewer** **2012-Present**
The journal of “***Middle East African Journal of Ophthalmology***”
Middle East African Council of Ophthalmology
- **Scientific Reviewer** **2018-2022-Presen**
The journal of “***Canadian Journal of Ophthalmology***”
Canadian Ophthalmological Society
- **Moderator** **2012**
Ocular Oncology Program
World Ophthalmology Congress WOC, Abu-Dahbi, UAE
- **Scientific Director, Controversies in Ophthalmology** **2013**
Eye Research Center
Iran University of Medical Sciences
- **Moderator** **2014**
Ocular Oncology Program
World Ophthalmology Congress WOC, Tokyo, Japan
- **Invited Chair** **2014**
Ocular Oncology Program
World Ophthalmology Congress WOC, Tokyo, Japan
- **Scientific Director** **2015**
25th Annual Congress of the Iranian Society of Ophthalmology
- **Head of International Affairs** **2013-2015**
The Iranian Society of Ophthalmology IrSO
- **Moderator** **2016**
Ocular Oncology Program
World Ophthalmology Congress WOC, Guadalajara, Mexico
- **Invited Chair** **2016**
Imaging in Ocular and Orbital Tumors
World Ophthalmology Congress WOC, Guadalajara, Mexico
- **Moderator** **2018**
Ocular Oncology Program
World Ophthalmology Congress WOC, Barcelona, Spain
- **Moderator** **2019**
Retina Subspecialty Day: New Horizons in Vitreoretinal Surgery
XXIX Annual congress of the Iranian society of ophthalmology

- **Moderator** **2021/06/17**
 Controversies in Recent Advances in the Diagnosis and Management of Intraocular Tumors (Webinar)
 IRSO Spring Ophthalmology Meeting
- **Moderator** **2021/07/30**
 Iranian Retina Society with Collaboration of Ocular Oncology Service of IUMS held: "Management of Uveal Melanoma" (Webinar)
- **Moderator** **2021/10/01**
 Retinoblastoma Management of Intraocular Tumors (Webinar)
 Iranian Vitreoretinal Society & Eye Research Center of IUMS
- **Moderator** **2021/10/16**
 Challenging Cases in Retinal Diseases and Surgery (Webinar)
 XXXI Annual Congress of the Iranian Society of Ophthalmology

Honor and Awards

- Second rank, **Iranian Board of Ophthalmology**, 1992, Iran
- Acquiring ***Iran Award*** in the Third Spring Ophthalmology Conference, 18th -20th April, 2019. Tehran, Iran
- Chosen as the ***Top Ophthalmology Professor***, 29th Annual Congress of the Iranian Society of Ophthalmology, 18th to 21st November 2019, Tehran, Iran
- Chosen as the ***Top Researcher***, Rasool Akram Hospital, Iran University of Medical Sciences, 20th January, 2020, Tehran, Iran
- Chosen as the ***Top Researcher***, Rasool Akram Hospital, Iran University of Medical Sciences, 28th December, 2021, Tehran, Iran

Publications

Articles

1. Naseripour M, Parvaresh MM. Predisposing factors of Retinal Detachment and Prophylactic Treatment. ***Iranian Ophthalmology Journal of Bina***, 1996; 1(4): 47-64.

2. Naseripour M, Parvaresh MM. Prophylactic Laser Treatment in Patients with Symptomatic Retinal Breaks. ***Iranian Ophthalmology Journal of Bina***, 1999; 4(2):128-133
3. Naseripour M, Parvaresh MM. Scleral buckling Result and Related Risk factors. ***Iranian Ophthalmology Journal of Bina***, 1999; 4(4): 335-340
4. Naseripour M, Iranfar S. Evaluation of Educational Activities of the Faculty of Kermanshah University of Medical Sciences from medical student's Standpoint. ***Iranian Journal of Behbood***, 2000; 4(3): 27-32
5. Naseripour M, Shields CL, Shields J, Guyer DR. Pseudohypopyon of Orange Pigment Overlying a Stable Choroidal Nevus. ***American Journal of Ophthalmology***, 2001; 132: 416-417.
6. Shields CL, Naseripour M, Shields J. Topical Mitomycin C for Extensive Recurrent Conjunctival-Corneal Squamous Cell Carcinoma. ***American Journal of Ophthalmology***, 2002; 133: 601-606.
7. Mirzazadeh A, Tavakoli S, Naseripour M. Comparison of Graduate Medical Education in Iran with WFME International Guidelines: Quality Improvement in Postgraduate Medical Education. ***Iranian Journal of Medical Education***, 2002; 8: 37-38.
8. Shields J, Shields CL, Naseripour M, Eagle RC, Miller J. Choroidal Melanoma in a Black Patient with Oculodermal Melanocytosis. ***Retina***, 2002; 22: 126-128.
9. Shields CL, Naseripour M, Shields J, Eagle RC. Topical Mitomycin C for Pagetoid Invasion of the Conjunctiva by Eyelid Sebaceous Gland Carcinoma. ***Ophthalmology***, 2002; 109: 2129-2133.
10. Shields CL, Naseripour M, Cater J, Shields J, Demirci H, Youseff A, Freire J. Plaque Radiotherapy for Large Posterior Uveal Melanomas in 354 Consecutive Patients. ***Ophthalmology***, 2002; 109: 1838-1849.
11. Shields CL, Naseripour M, Shields J, Freire J, Cater J. Custom-Designed Plaque Radiotherapy for Nonresectable Iris Melanoma in 38 Patients: Tumor Control and Ocular Complications. ***American Journal of Ophthalmology***, 2003; 135: 648- 656.
12. Panda, A., Bajaj, M.S., Balasubramanya, R., Prakash, G., Shields, C.L., Naseripour, M., Shields, J.A. Topical mitomycin C for conjunctival-corneal squamous cell carcinoma [1] (multiple letters). ***American Journal of Ophthalmology***, 2003; 135 (1), pp. 122-124.
13. Naseripour M, Parvaresh MM, Bakhtiari P, Afsar N. Transpupillary Thermotherapy for Treatment of Occult Subfoveal Choroidal Neovascularization in Age Related Macular Degeneration. ***Iranian Journal of Ophthalmology***, 2004; 17(3):49-57.
14. Mirzadeh A, Hashemi H, Naseripour M, Fotouhi A, Yazdani K, Tavakoli S, Raisi B, Taj M. Establishment of New Evaluation and Accreditation System

- for Graduate Medical Education in Iran. *Journal of Medical Education*, 2004; 5(2):69-73.
15. Naseripour M. Bakhtiari P, Mogadam AZ, Vosogh P, Naseripour Majid, Salimi S. Combined chemoreduction and adjuvant therapy to control advanced retinoblastoma. *Iranian Journal of Ophthalmology*, 2005; 18(4.): 91-98.
 16. Naseripour M. Retinoblastoma. *Iranian Journal of Ophthalmology*, 2006; 19(1.): 35-48.
 17. Naseripour M. Ansari MR, Sheikhi F, Danesghgar F, Omidian J, Ghaderi E. Retinopathy Prevalence and Its Risk Factors in Diabetics at Kermanshah Diabetes Research Center (1994-2000). *Iranian Journal of Behbood*, 2006; 9(4): 44-51.
 18. Naseripour M. Bakhtiari P, Salimi S, Kashkouli MB, Sadeghipour AR. Rubeosis iridis complicating acquired astrocytoma of solitary optic nerve head; A clinicopathologic case report. *Iranian Journal of Ophthalmology*, 2006; 19:60-64.
 19. Sanjari S, Falavarjani GK, Parvaresh MM, Modarres-zadeh M, Naseripour M. Nojomi M. Vitreopapillary Traction in Non-arteritic Anterior Ischemic Optic Neuropathy. *Bina Journal of Ophthalmology*, 2006; 11(3):289-293
 20. Sanjari MS, Falavarjani KG, Parvaresh MM, Modarres Zadeh M, Naseripour M. Nojomi M. Vitreopapillary Traction in Nonarteritic Anterior Ischemic Optic Neuropathy. *Iranian Journal of Ophthalmic Research*, 2006; 1(2): 110-112.
 21. Naseripour M. falavarjani KG, Akbarzadeh S. Retinocytoma Associated with Bilateral Retinoblastoma. *Bina Journal of Ophthalmology*, 2007; 1 (13):130-132.
 22. Kashkouli MB, Salimi S, Aghaee H, Naseripour M. Bilateral pseudomonas aeruginosa endophthalmitis following bilateral simultaneous cataract surgery. *Indian Journal of Ophthalmology*, 2007; 55 (5):374-375.
 23. Kashkouli MB, Reaee R, Nilforoushan N, Salimi Sh, Foroutan AR, Naseripour M. Topical Antiglaucoma Medications and Lacrimal Drainage system obstruction. *Ophthalmic Plastic & Reconstructive Surgery*, 2008; 24 (3):172-5.
 24. Sadeghipour AR, Abolhasani M, Naseripour M. Association of Vessel Density and Vascular Endothelial Growth Factor with Local Invasive Growth in Ocular Retinoblastoma, Hazrat Rasool Akram Hospital 2000-2006. *Journal of Iran University of Medical Sciences*, 2008; 57 (14): 133-141.25.
 25. Naseripour M. Akbarzadeh S, Ahadian A, Vosough P. The Role of periocular carboplatin in treatment of advanced intraocular retinoblastoma. *Iranian Journal of Ophthalmology*, 2008; 20(1):16-19.

26. Kashkouli MB, Salimi S, Bakhtiari P, Parvaresh MP, Sanjari MS, Naseripour M. EMLA Cream Application without Occlusive Dressing Before upper facial Botulinum Toxin Injection. A Randomized Double-Blind Placebo-Controlled Trial. ***Annals of plastic Surgery***, 2008; 60(4):353-356.27.
27. Naseripour M, Nazari H, Bakhtiari P, Modarres Zadeh M, Vosough P, Ansari M.R, Ahadian A. Outcomes and Prognosis of Treatment for Retinoblastoma with Primary Chemotherapy and Focal Treatment. ***Bina Journal of Ophthalmology***, 2008; 14(1): 3-9.
28. Modarres Zadeh M, Naseripour M, Falavarjani KG, Nikeghbali A, Hashemi M, Parvaresh MM. Two Different Doses of Intravitreal Bevacizumab for Treatment of Choroidal Neovascularization Associated with Age Related Macular Degeneration. ***Journal of Ophthalmic and Vision Research***, 2008; 3(2): 102-107.
29. Naseripour M, Nikeghbali A, Vadipour A, Bakhtiari P, Ahadian A. Combined Tranpupillary thermotherapy with subtenon triamcinolone injection in treatment of choroidal neovascularization secondary to exudative age related macular degeneration. ***Armaghane Danesh Journal***, 2008; 13 (1): 1-13.
30. Naseripour M, Kashkouli MB, Jaberi MS, Aghaee GH, Ahadian A. Plaque Radiotherapy in Recurrent or Incomplete-Excised Conjunctival Squamous Cell Carcinoma and Melanoma. ***Iranian Journal of Ophthalmology***, 2008; 20 (3): 19-23.
31. Naseripour M, Akbarzadeh S, Bakhtiari P, Ahadian A. Adjuvant Effects of Periocular Chemotherapy in Treatment of Advanced Intraocular Retinoblastoma. ***Journal of Iran University of Medical Sciences***, 2008; 62(16)187-193.
32. Naseripour M, Nazari H, Bakhtiari P, Modarres M, Vosough P, Ausari M. Retinoblastoma in Iran: outcomes in terms of patients' survival and globe survival. ***British Journal of Ophthalmology***, 2009; 93 (1):28-32.
33. Modares-zadeh M. Naseripour M, Falavarjani KG, Nikeghbali A, Hashemi M, Parvaresh MM. Intravitreal Injection of 2.5 mg VERSUS 1.25 mg Bevacizumab (Avastin) for Treatment of Choroidal Neovascularization(CNV) Associated with Age-related Macular Degeneration (AMD). ***Retina***, 2009; 29(3): 319-24.
34. Naseripour M, Falavarjani KG, Mirfallah K, Bagheri SR. Photodynamic therapy for vasoproliferative tumors and capillary hemangiomas of retina. ***Bina Journal of Ophthalmology***, 2009; 14(2): 109-115.
35. هانیة محمد رضا، صدیقه مرجانه حجازی، محمد علی عقابیان، علیرضا احمدیان، مسعود ناصری پور، محمد رضا زرین، خلیل قاسمی فلاورجانی، حسین نظری. اندازه گیری مساحت عروق تازه تشکیل شده ناشی از بیماری استحالہ وابسته به سن ماکولا با استفاده از روش آستانه گذاری اتسو تغییر یافته. **مجله فیزیکی پزشکی ایران**، دوره 5 شماره 2، پیاپی (20،21)، پاییز و زمستان 87.

36. Nazari H, Modarres Zadeh M, Kashkouli MB, Naseripour M, Parvaresh MM, Nazari P. Central retinal artery perfusion following 0.1 ml intravitreal injection of Bevacizumab. *Iranian Journal of Ophthalmology*, 2009;21(2):13-18.
37. Naseripour M, Nazari H, Bakhtiari P, Ahadian A, Jaberi R. Ruthenium 106 Plaque for retinal vasoproliferative tumors. *Iranian Journal of Ophthalmology*, 2009;21(2):31-35.
38. Saadat S, Naseripour M, Rahimi B. Safety preparedness of urban community for new year fireworks in Tehran. *Burns*, 2009; 35: 719-722.
39. Modarres M, Nazari H, Falavarjani KG, Naseripour M, Hashemi M, Parvaresh MM. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. *European Journal of Ophthalmology*, 2009; 19: 848-852.
40. Naseripour M, Falavarjani GH, Oladi MR, Modarre M. Testing Toxicity of Intravitreal Bevacizumab (Avastin) used for the Treatment of Choroidal Neovascularization Associated with Age-Related Macular Degeneration: A Full Field ERG Study. *Iranian Journal of Ophthalmology*, 2009;21(3):49-55
41. Falavarjani KG, Nikeghbali A, Modarres Zadeh M, Hashemi M, Parvaresh MM, Naseripour M. Long Term Results of Fixation of Dislocated Intraocular Lenses Using Haptic Externalization Through a Clear Corneal Incision. *Iran University of Medical Sciences*, 2009; 63 (16): 169-175
42. Naseripour M, Falavarjani KG, Bakhtiari P, Vosough P, Aryad F. Retinoblastoma survival in Iran 10 years experience of a referral center. *Iranian Journal of Ophthalmology*, 2009;21(4):17-24.
43. Saadat S, Naseripour M, Smith GA. The health and economic impact of fireworks-related injuries in Iran: a household survey following the New Year's Festival in Tehran. *Injury*, 2010;41(7):e28-33.
44. Naseripour M, Falavarjani KG, Akbarzadeh S. Retinocytoma associated with bilateral retinoblastoma. *Indian Journal of Ophthalmology*, 2010;58(2):155-156.
45. Saadat S, Naseripour M, Karbakhsh M, Rahimi Movaghar V. Perceived risk and risk-taking behavior during the festival firework. *American Journal of Health Behavior*, 2010;34(5): 525-531.
46. Falavarjani KG, Mohammadreza H, Marjaneh Hejazi S, Naseripour M. A Modified Semiautomatic Method for Measurement of Hyperfluorescence Area in Fluorescein Angiography. *Iranian Journal of Ophthalmology*, 2010;22(4):73-79.
47. Falavarjani KG, Naseripour M. New hope for retinoblastoma patients. *Journal of Ophthalmic and Vision Research*, 2010;5(3):213-214.

48. Falavarjani KG, Modarres M, Nazari H, Naseripour M, Parvaresh MM. Diabetic macular edema following panretinal photocoagulation. **Archives of Ophthalmology**, 2010;128(2):262;
49. Samiy N, Harandi ZA, Naseripour M, Lai TY. Bilateral elevated macular lesions. **Journal of Ophthalmic and Vision Research**, 2011;6(1):55-62.
50. Naseripour M. Retinoblastoma survival disparity”: The expanding horizon in developing countries. **Saudi Journal of Ophthalmology**, 2012; 26, 157-161.
51. Kashkouli MB, Heirati A, Pakdel F, Kiavash V, Naseripour M, Aghamohammadi F. Long-term follow-up of invasive ocular surface squamous cell carcinoma treated with excision, cryotherapy, and topical mitomycin C. **Graefe's Archive for Clinical and Experimental Ophthalmology**, 2012; 250 (10):1527-1532.
52. Saliminejad K., Behna B., Akbari M.T., Khorshid H.R.K., Ghassemi F., Amoli F.A., Akhondi M.M., Vosoogh P., Naseripour M, Ahani A. Rapid detection of RB1 recurrent mutations in retinoblastoma by ARMS-PCR. **Journal of Genetics**, 2013;92(2): e36-40.
53. Falavarjani KG., Modarres M, Hashemi M, Parvaresh MM, Naseripour M, Zare-Moghaddam A, Nekoozadeh S. Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinical center. **Retina**, 2013; 33 (5): 971-974.
54. Ahani A, Akbari MT, Saliminejad K, Behnam B, Akhondi MM, Vosoogh P, Ghassemi F, Naseripour M, Bahoush G, Khorshid HRK. Screening for large rearrangements of the RB1 gene in Iranian patients with retinoblastoma using multiplex ligation-dependent probe amplification. **Molecular Vision**, 2013; 19: 454-462.
55. Ghasemi Falavarjani K, Hashemi M, Modarres M, Parvaresh MM, Naseripour M, Nazari H, Jalili Fazel A. Vitrectomy for Posterior Segment Intraocular Foreign Bodies, Visual and Anatomical Outcomes. **Middle East African Journal of Ophthalmology**, 2013; 20(3): 244–247.
56. Ali Kord Valeshabad A, Naseripour M, Asghari R, Parhizgar SH, Parhizgar SE, Taghvaei M5, Miri S. Enucleation and evisceration: indications, complications and clinicopathological correlations. **International Journal of Ophthalmology**, 2014 18;7(4):677-680.
57. Falavarjani KG, Agha Mirsalim M, Modarres M, Hadavand Kahani A, Hashemi M, Parvaresh MM, Naseripour M, Samiy N. Endophthalmitis after resident-performed intravitreal bevacizumab injection. **The Canadian Journal of Ophthalmology**, 2015; 50(1):33-6.
58. Ghasemi Falavarjani K, Alemzadeh SA, Modarres M, Parvaresh MM, Hashemi M, Naseripour M, Nazari Khanamiri H, Askari S. Scleral buckling surgery for rhegmatogenous retinal detachment with subretinal proliferation. **Eye (Lond)**, 2015;29(4):509-14.

59. Naseripour M. Mehrazma M, Pourmatin R, Bahmani Kashkouli M, Sedaghat A, Gheytnchi E. Monosomy 3 by chromogenic in situ hybridization (CISH) in Iranian patients with uveal melanoma, ***Journal of Current Ophthalmology***, 2015; 27(1-2): 41 - 4
60. Naseripour M. Ghasempour A, Falavarjani KG, Sanjari MS, Yousefi M. Perfluorocarbon liquid migration into the subarachnoid space in a patient with morning glory syndrome. ***Journal of Current Ophthalmology***, 2015;27(1-2):60-2.
61. Naseripour M. Abrishami M, Sedaghat A, Abrishami M, Rezaei Kanavi M, Mosallaei N, Ghasemi FalavarjaniK, Pourmatin R, Safarian O, Malaekheh-Nikouei B. Preparation and in vivo evaluation of nanoliposomes containing melphalan after intravitreal injection in albino rabbits. ***Journal of Pharmaceutical Investigation***, 2016; 46:575–582.
62. Naseripour M. Jaberi R, Sedaghat A, Azma Z, Nojomi M, Ghasemi Falavarjani K, Nazari N. Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate, ***Journal of Contemporary Brachytherapy***, 2016; 8, 1: 66–73.
63. Naseripour M. Aghaei H, Sedaghat A, Kheirkhah A, Jaberi R, Azma Z. Corneal Patch Graft: A New Approach for Scleral Necrosis Secondary to Plaque Radiotherapy. ***Cornea***, 2016;35(4):565-568.
64. Naseripour M. Ghasemi Falavarjani K, Sedaghat A, Karimi Moghaddam A, Nasserisina S, Alemzadeh SA. Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. ***Journal of Ophthalmic and Vision Research***, 2016; 11 (1): 66-69.
65. Ghasemi Falavarjani K, Alemzadeh SA, Modarres M, Alemzadeh SA, Parvarash MM, Naseripour M. Hashemi M, Robotmeili M. Outcome of surgery in patients with giant retinal tear: 10 years experience. ***Eye (Lond)***, 2017;31(9):1284-1289.
66. Naseripour M. Hamidian R, Smith GA, Saadat S. Effectiveness of Educational Interventions on Fireworks-related Injuries among Schoolboys. ***American Journal of Health Behavior***, 2017;41(3):223-227.
67. Shahraki K, Ahani A, Sharma P, Faranoush M, Bahoush G, Torktaz I, Gahl WA, Naseripour M. Behnam B. Genetic screening in Iranian patients with retinoblastoma. ***Eye (Lond)***, 2017;31(4):620-627.
68. Hedayatfar A, Falavarjani KG, Soheilian M, Elmi Sadr N, Modarres M, Parvaresh MM, Naseripour M. Rohani M, Almasi M, Chee SP. Mycophenolate Mofetil for the Treatment of Multiple Sclerosis-associated Uveitis. ***Ocular Immunology and Inflammation***, 2017;25(3):308-314. Epub 2016 Jul 5.
69. Ilka R, Mohseni M, Kianirad M, Naseripour M. Ashtari K, Mehravi B. Nanogel-based natural polymers as smart carriers for the controlled

- delivery of Timolol Maleate through the cornea for glaucoma. *International Journal of Biological Macromolecules*, **2018**;109:955-962.
70. Naseripour M, Maleki A, Astaraki A, Sedaghat A, Jaber R, Lee S, Azma Z, Silpa-Archa S. Ruthenium-106 brachytherapy in the treatment of circumscribed choroidal hemangioma. *Retina*, **2018**; 38 (5):1024–1030.
71. Malakouti SK, Naseripour M, Nemati Anaraki L. A critique or violation of the past research country. *Rahyaf*, **2018**; 28 (70):21-35.
72. Dehdashtian E, Mehrzadi S, Yousefi B, Hosseinzadeh A, Reiter RJ, Safa M, Ghaznavi H, Naseripour M. Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress. *Life Science*, **2018**;15(193):20-33.
73. Naseripour M, Abdolalizadeh P, Abdi F, Mehrvar A, Tashvighi M. Serous retinal detachment as an initial presentation of childhood acute myeloid leukemia. *The Canadian Journal of Ophthalmology*, **2019**;54(4):e170-e173.
74. Aliakbar Navahi R, Babaheidarian P, Sedaghat A, Naseripour M, Aghai G, Mardani A, Ahangaranic M. Retinal anaplastic pleomorphic xanthoastrocytoma unassociated with phakomatosis. *Journal of Current Ophthalmology*. *Journal of Current Ophthalmology*, **2019**; 31:234-237.
75. Javanmard D, Moein M, Esghaei M, Naseripour M, Monavari SH, Bokharaei-Salim F, Sadeghipour A. Molecular evidence of human papillomaviruses in the retinoblastoma tumor. *VirusDisease*, **2019**; 30(3):360–366.
76. Juybari KB, Hosseinzadeh A, Ghaznavi H, Kamali M, Sedaghat A, Mehrzadi S, Naseripour M. Melatonin as a modulator of degenerative and regenerative signaling pathways in injured Retinal Ganglion Cells. *Current Pharmaceutical Design*, **2019**; 25(17):3057-3073.
77. Naseripour M, Ghasemi Falavarjani K, Mirshahi R Et al. Optical coherence tomography angiography (OCTA) applications in ocular oncology. *Eye (Lond)*, **2020**; 34(9):1535-1545.
78. Abolfath Zadeh N, Naseripour M, Jaber R, Azma A, Alemzadeh SA, Arbab M, Sedaghat A. Ru-106 plaque radiotherapy for vasoproliferative tumors of retina: a 15-year single-center experience. *International Ophthalmology*, **2020**; 40: 2095-2102.
79. Ghasemi Falavarjani K, Hadavand Kahani A, Parvaresh MM, Modarres M, Naseripour M, Alemzadeh SA. Intra-silicone Oil Injection of Methotrexate in Retinal Reattachment Surgery for Proliferative Vitreoretinopathy. *Ocular Immunology and Inflammation*, **2020**;28(3):513-516
80. Shahriari M, Mehrzadi S, Naseripour M, Fatemi I, Hosseinzadeh A, Kanavi MR, Ghaznavi H. Beneficial effects of melatonin and atorvastatin on retinopathy in streptozotocin-induced diabetic rats. *Current Drug Therapy*, **2020**;15 (4). pp. 396-403.

81. Naseripour M, Sedaghat A, Abdolalizadeh P, Azizi E. Treatment Outcome of Acquired Retinal Pigment Epithelial Tumors with Ruthenium-106 Plaque Radiotherapy: Experience on Two Cases. ***Journal of Current Ophthalmology***, 2020;32(3): 297-301.
82. Faranoush M, Mehrvar N, Tashvighi M, Fabian ID, Zloto O, Bascaran C, Ghorbani R, Ghasemi F, Naseripour M, Sedaghat A, Alebouyeh M, Mehrvar A. Retinoblastoma presentation, treatment and outcome in a large referral center in Tehran: a 10-year retrospective analysis. ***Eye (Lond)***, 2021; 35(2):575-583.
83. Mirshahi R, Anvari P, Riazi-Esfahani H, Sardarinia M, Naseripour M, Ghasemi Falavarjani K. Foveal avascular zone segmentation in optical coherence tomography angiography images using a deep learning approach, ***Scientific Reports***, 2021; 11(1):1-8.
84. Tabibzadeh A, Naseripour M, Karbalaie Niya MH, Javanmard D, Sadeghipour A, Esghaei M. Molecular Investigation of the Human Adenovirus in Retinoblastoma Patients. ***International Journal of Medical Laboratory***, 2021;8(2):96-102.
85. Abri Aghdam K, Sanjari MS, Naseripour M, Manafi N, Sedaghat A, Bakhti. The Impacts of Episcleral Plaque Brachytherapy on Ocular Motility. ***Journal of Binocular Vision and Ocular Motility***, 2021;71(2):
86. Aghaei H, Sedaghat A, Abolfath Zadeh N, Mirshahi R, Manaf N, Kiaee Afshar R, Naseripour M. Short-term changes of cornea and tear film after ruthenium-106 plaque therapy for intraocular tumors, ***Indian Journal of Ophthalmology***, 2021; 69(12):3469-3472.
87. Naseripour M, Sedaghat A, Mirshahi R, Abdolalizadeh P, Koushki A, Faranoush M, Ghorbani M, Bahmani Kashkouli M, Sadeghipour A, Chaibakhsh S and Mehrvar A. Targeted chemotherapy in retinoblastoma: A step forward from patient survival to globe survival European ***Journal of Ophthalmology***,2022; online ahead of publication
88. Dehghan S, Mirshahi R, Shoaee-Hassani A and Naseripour M Human-induced pluripotent stem cells-derived retinal pigmented epithelium, a new horizon for cells-based therapies for age-related macular degeneration ***Journal of Stem Cell Research & Therapy***, 2022; 13:217
89. Mirshahi R, Sedaghat A, Jaber R, Azma Z, Mazloumi M, Naseripour M Ruthenium-106 plaque radiotherapy for uveal melanoma: analysis of tumor dimension and location on anatomical and functional results ***Journal of BMC Ophthalmology (2022) 22:309***
90. Azimi F, Mirshahi R, Naseripour M Review: New horizons in retinoblastoma treatment: an updated review article ***Journal of Molecular Vision 2022; 28:130-147***

91. Mohseni M, Shojaei Y, Naseripour M, Delavar F, Mirzaei M and Mehravi B Lauric acid-grafted biopolymeric nanoparticles for efficient Melphalan delivery across the corneal layers for retinoblastoma: ex vivo and in vivo permeation study ***Journal of Nanosci. Nanotechnol.* 13 (2022) 035005 (11pp)**
92. Naseripour M, Azimi F, Taleb Si, Mirshahi R, Kiaee R, Sedaghat A, Ataei Kachoei Z, Khakpoor G
The spectrum of germline VHL variants in Iranian patients with Retinal Capillary Hemangioblastoma and genotype-phenotype analysis ***Journal of Research Square Preprints***
93. Naseripour M, Hemmati S, Chaibakhsh S, Gordiz A, Miri L and Abdi F Cystoid macular oedema without leakage in fluorescein angiography: a literature review ***Journal of Springer Nature EYE***
94. Mirshahi R, Naseripour M, Shojaei A, Heirani M, Alemzadeh A, Moodi F, Anvari P & Falavarjani KH. Differentiating a pachychoroid and healthy choroid using an unsupervised machine learning approach ***Journal of Nature Portfolio Scientific Reports | (2022) 12:16323 |***
95. Naseripour M, Khakpoor G, Bagherzadeh K, Sedaghat A, Mirshahi R, Kasraee H, Afshar Kiaee R, Azimi F. In Silico Analysis of Novel VHL Germline Mutations in Iranian RCH Patients Running title: In Silico Analysis of Novel VHL Mutations in RCH Patients ***Journal of bioRxiv***
96. Mohseni M, Shojaei Y, Naseripour M, Delavar F, Mirzaei M, Mehravi B, Lauric acid-grafted biopolymeric nanoparticles for efficient Melphalan delivery across the corneal layers for retinoblastoma: ex vivo and in vivo permeation study ***Journal of Advances in Natural Sciences: Nanoscience and Nanotechnology*** در حال حاضر فول تکست مقاله آنلاین نشده

Books

1. Masood Naseripour and Arun D.Singh, **Retinoblastoma: Enucleation Chapter in” Pocket Guild to Ocular Oncology and Pathology”** by Hans E.Grossniklaus. Springer Heidelberg New York Dordrecht London ISBN 978-3-642-28911-8, **2012**.
2. Masood Naseripour, General Ophthalmology, Chapter Twenty-six **”Intraocular tumors”**, **2013**
3. Masood Naseripour, **”Clinical Ophthalmic Oncology”**, Second and Third Edition, Chapter 23, **”Uveal Vascular Tumors”**. Springer-Verlag Berlin Heidelberg **2014**. DOI 10.1007/978-3-642-54255-8_23.
4. Masood Naseripour, Azadeh Memarian. **Medical Malpractice in Ophthalmology and how to avoid it**. Kamran Aghakhani, **2017**

5. Masood Naseripour, "**Clinical Ophthalmic Oncology**", Third Edition, Chapter 23 "**Uveal Vascular Tumors**". Springer-Verlag Berlin Heidelberg **2019**
6. Pasha Anvari, Masood Naseripour, Khalil Ghasemi Falavarjani. **Choroidal Neovascularization Associated with Rare Entities Choroidal Neovascularization**. pp 237-256,

Research Projects

NO.	Project Name	Year
1	Congenital Cataract Incidence in Tabriz	1992
2	Diabetic Retinopathy Cumulative Incidence Rate and Related Risk factors in "Diabetic Research Center" patients	1993
3	Efficacy of Argon laser Trabeculoplasty in Primary Open Angle Glaucoma	1995
4	Epidemiological Study of Diabetic retinopathy and risk factors since Diagnosis in diabetic patients of Kermanshah Diabetic Research center	1999
5	Health and Diseases Evaluation in Community Based Medical Education Field in Kermanshah	1999
6	Efficacy of Transpupillary Thermotherapy for Occult Sub-foveal CNV	2003
7	Efficacy of Sub Threshold Grid Laser photocoagulation in Patients with symptomatic	2003
8	Macular thickness and retinal nerve fiber layer thickness evaluation following brachytherapy of intra-ocular tumors	2004
9	Combined chemoreduction and periocular carboplatin in treatment of advanced retinoblastoma	2004
10	The Determination of prevalence of eye related macular degeneration in population after than 40 years old in Kermanshah province in 2005	2005
11	The evaluation of the results of ruthenium 106 plaque radiotherapy for the treatment of intraocular choroidal malignant melanoma	2005
12	Comparison of different dose (1.25 and 2.5mg) of intravitreal Bevacizumab (Avastin) with combined intravitreal Avastin (1.25 mg) and Triamcinolon (2 mg) in exudative age-related macular degeneration. A double-blind clinical trial.	2005
13	Incidence rate of injuries due to fire work at last Wednesday of solar year in Tehran.	2005
14	The investigation of outcomes and prognosis of patients with Retinoblastoma following primary chemoreduction and focal treatment based on International (A-E) classification	2006
15	Electrophysiologic findings (GERG) after interavitreal Avastin (Bevacizumab) treatment in choroidal neovascular membrane.	2007
16	The evaluation of the Photodynamic therapy for retinal vascular tumors of retina	2008
17	Designing and development of a calculating system to measure the hyperfluorescent areas in retinal angiography.	2008
18	Investigation of Sandwich therapy for Choroidal Melanoma	2008
19	Comparative study of disease-free ratio in the patients with uvula melanoma and monosomy-3 with and without adjuvant therapy (temozolamid and peginterferon α -2b).	2008
20	The evaluation of the results of primary transpupillary thermotherapy in posterior pole small choroidal melanomas.	2008
21	Detection of Mutations in total exon and promotor of the Rb1 gene in hazrate rasol hospital retinoblastoma patients by using exon by exon PCR-SSCP analysis	2008
22	Photodynamic therapy for retinal vasoproliferative and angiomatous tumors of retina	2009

23	Results of vitrectomy and removal of foreign bodies inside the eye during the last 5 years in Rasool Akram Hospital	2011
24	Evaluation of the frequency of monosomy 3 in patients with uvea melanoma using CISH technique in patients referred to Rasoul hospital from 2002 to 2012	2011
25	Preparation and evaluation of in vivo (nano-liposomes containing melphalan) following intravitreal injection	2011
26	Investigating the effect of intravitreal injection of ovastin on macular ischemia in patients with diabetic macular edema	2011
27	Evaluation of nerve fiber layer thickness in patients with diabetic macular edema after macular laser	2011
28	Evaluation of changes in visual field before and after scleral buckling surgery	2011
29	Aspects of ocular manifestations of choroidal metastases in patients referred to the oncology center of Rasoul Akram Hospital	2011
30	Comparison of the effect of vitrectomy with 20 and 23 gauge methods on corneal sensation	2011
31	Analysis of ocular survival in children with retinoblastoma using a semi-parametric Cox multivariate model	2012
32	Application of bivariate negative binomial regression model in retinal tumor data	2012
33	Ocular survival analysis of children with retinoblastoma using fragility model	2012
34	Evaluation of safe amounts of in vitro injection of doxycycline in rabbit's eyes	2013
35	Evaluation of the results of treating patients with chronic central serous chorioretinopathy (CSCR) referred to the specialized eye clinic and hospital of Rasoul Akram Hospital by photodynamic therapy with half-dose verteporfin from January 2010 to May 2014	2014
36	Determination of genetic mutations related to VHL (Van Hippel Lindo) gene in patients with retinal capillary hemangioma in Rasoul Akram Hospital, Tehran	2015
37	Evaluation of the role of NMDA receptor in the protective effect of melatonin in streptozotocin-induced diabetic retinopathy in rats	2016
38	Design and fabrication of phantoms and preparation of reference protocol for dosimetry of Ru106 radioactive ocular plaques using radiochromic film, TLD, Ionization Chamber, MOSFET dosimeters	2016
39	The effect of physical exercise on cognitive, motor and visual function in people with Parkinson's disease and the corresponding animal model	2017
40	Survival rate of patients with retinoblastoma regarding changes in their therapeutic trend in patients referred to Rasoul Akram Hospital in from 2002 to 2017	2017
41	Evaluation of changes in the dominant bacterial microbiome of patients with conjunctival squamous cell carcinoma compared with healthy individuals	2017
42	Molecular diagnosis of human adenovirus in retinal tumor specimens in patients with retinoblastoma cancer	2017
43	Study of the effects of concomitant administration of melatonin and atorvastatin on streptozotocin-induced diabetic retinopathy in rats	2017
44	Evaluation of the predominant microbiota of people with HPV positive and HPV negative bacterial vaginosis compared to healthy people	2017
45	Evaluation of serum vimentin and nestin levels as a biomarker Early detection of liver metastasis in ocular melanoma	2017
46	Imaging of posterior segment tumors of the eye with multimodal imaging approach	2017
47	Design and synthesis of new drug delivery systems (biocompatible and biodegradable implants with long-term release power) and evaluation of their toxicity	2017
48	Design and manufacture of soft contact lenses containing polymer nanoparticles for the treatment of glaucoma	2017
49	Preparation of reference protocol for dosimetry of radioactive ocular plaques Ru 106 using different dosimeters	2017

50	Evaluation of the results of intra-arterial chemotherapy in patients with retinoblastoma: 6-year report	2017
51	Genomics analysis in patients with uveal melanoma to evaluate genomic factors related to disease prognosis	2018
52	Genetic analysis of Iranian families with retinal capillary hemangioma	2018
53	Evaluation of the effect of photothermal therapy of glucose-bound gold nanoshell on retinoblastoma cancer cells model y79	2018
54	Simulation of visits of patients with suspected COVID-19 disease in an ophthalmology clinic	2019
55	Evaluation of clinical biomarkers and predictive imaging of response to treatment with photodynamic therapy of half dose (PDT) in patients with central serous chorioretinopathy (CSCR)	2019
56	Estimation of uveal melanoma incidence in the world using meta-analysis	2019
57	Molecular evaluation of dominant's microbial bacteria in patients with conjunctival squamous cell carcinoma	2019
58	Evaluation of the genotype-phenotype relationship of patients with Van Hippel Lindo (VHL): a meta-analysis study	2019
59	Comparison between the results of half-dose photodynamic therapy with vertporphine based on indocyanine green and fluorescein angiography in central ocular chorioretinopathy	2020
60	Investigation of the possibility of cell therapy in optic neuropathy caused by glaucoma	2020
61	Structural study of new mutations observed in RCH patients referred to the ophthalmology clinic of Rasoul Akram Hospital and their effect on pVHL protein function: Molecular docking and molecular dynamics simulation	2020
62	Direct differentiation of embryonic stem cells into retinal pigmented epithelial cells to be used in macular age-based cell transformation-based treatment project	2020

Conference Presentations

1. **Naseripour M**, Deep Vitrectomy Result in Patients with Active PDR. 4th National Ophthalmologic seminar, Tehran, Iran **1994**
2. **Naseripour M**, Episcleral Balloon in Patients with Retinal Detachment. 5th Ophthalmology Congress, Tehran, Dec. **1995**
3. **Naseripour M**, Retinal Detachment Management by Episcleral Parabolbar Balloon. The First Report from Iran. The First International Ophthalmology Congress, Tehran-Iran, **1995**
4. **Naseripour M**, Prognostic Factors in Intraocular Foreign Bodies. 7th Iranian Ophthalmologic Congress, Isfahan, Iran. **1997**
5. **Naseripour M**, Results of Prophylactic Laser therapy in retinal detachment. 8th Ophthalmologic Congress, Tehran, Iran. **1998**
6. **Naseripour M**, Scleral buckling Result and Prognostic Factors. 8th Ophthalmologic seminar, Tehran, Iran **1998**
7. **Naseripour M**, New in Retinoblastoma. Second International Ophthalmology Congress, Tehran-Iran, **2001**
8. **Naseripour M**, Management of Choroidal Malignant Melanoma. 2nd International Ophthalmology Congress, Tehran, Iran, **2001**

9. **Naseripour M**, Health and Diseases Status in Aged People in Community Oriented Medical Education Field in Kermanshah. 2nd Health and Preventive Medicine Seminar, Kermanshah, Iran, **2001**.
10. **Naseripour M**, Prevalence of Abnormal Red Reflex in Community Based Medical Education Field in Kermanshah. Kermanshah, Dec. **2001**
11. **Naseripour M**, Retinoblastoma: Early Diagnosis or Presenting Symptoms Education? 23rd Congress of advances in Pediatric, Tehran, May **2002**
12. **Naseripour M**, Evaluation of Patients with Intraocular Tumor. Tehran, Iran, Feb **2002**.
13. **Naseripour M**, Analytic Comparison of New Accreditation System for Graduate. Medical Education in Iran with ACGME and RCPSC Ahwaz, **2002**
14. **Naseripour M**, How to Approach to a Patient with Intraocular Tumor. Shahid Beheshti UMS. Tehran, Feb **2002**.
15. **Naseripour M**, Transpupillary Thermotherapy for Treatment of Occult Choroidal Neovascularization. 13th Ophthalmology Congress, Tehran, Dec. **2003**.
16. **Naseripour M**, Partial Lamellar Sclerouvectomy for Management of ciliary Body tumors. 13th Ophthalmology Congress, Tehran, Dec. **2003**
17. **Naseripour M**, Transpupillary Thermotherapy for Management of Choroidal Melanoma. 13th Ophthalmology Congress, Tehran, Dec. **2003**
18. **Naseripour M**, Partial Lamellar Sclerouvectomy: A Safe Procedure for Saving the Eyes with Ciliary Body Tumor. XI International Congress of Ocular Oncology, Hyderabad, India, Jan **2004**
19. **Naseripour M**, Are Combined Chemoreduction and Adjuvant Treatment Sufficient to Control the Patients with Advanced Retinoblastoma? XI International Congress of Ocular Oncology, Hyderabad, India, Jan **2004**
20. **Naseripour M**, Visual Results Following Transpupillary Thermotherapy of Choroidal Neovascularization In Patients with Exudative ARMD. 4th EURETINA Congress, Milan, Italy, May **2004**.
21. Transpupillary Thermotherapy of Occult and Classic Choroidal Neovascularization in Patients with Age-Related Macular Degeneration. **Naseripour M**, Parvaresh M.M, Bakhtiari P, Afsar N. 14th Iranian Congress of Ophthalmology 14-17 December **2004** Tehran
22. Ruthenium 106 Plaque Radiotherapy in Intraocular Tumors. **Naseripour M**, Tarassoli K, Jaber R, Samiee F, Dec 2004. 14th Iranian Congress of Ophthalmology 14-17 December **2004** Tehran.

23. Combined Chemoreduction and Adjuvant Therapy to Control Retinoblastoma. **Naseripour M**, Bakhtiari P, Zare Moghadam A, Vosough P. Dec 2004. 14th Iranian Congress of Ophthalmology 14-17 December **2004** Tehran
24. Optic Disc Astrocytoma Case Report. **Naseripour M**, Bakhtiari P, Imani M, Dec 2004. 14th Iranian Congress of Ophthalmology 14-17 December **2004** Tehran
25. Medulloepithelioma of Ciliary Body. **Naseripour M**, Bakhtiari P, ZareMoghadam A, Dec 2004. 14th Iranian Congress of Ophthalmology 14-17 December **2004** Tehran
26. Surgical and Anatomic Outcome of Pars Plana Vitrectomy with Silicon Oil Tamponade without Buckle Placement for the Treatment of Primary Rhegmatogenous Retinal Detachment, Parvaresh MM, **Naseripour M**, Bakhtiari P. 20th ASIA Pacific Academy of Ophthalmology Congress, **2005**.
27. Prevalence and Risk Factors of Supra-Choroidal Hemorrhage in Scleral Surgery. Bakhtiari P, Parvaresh MM, **Naseripour M**, 20th ASIA Pacific Academy of Ophthalmology Congress, **2005**.
28. Ruthenim 106 plaque radiotherapy in treatment of choroidal tumor. **Naseripour M**, Bakhtiari P, Jaber R, Kheirkhah R, Samiee F. International VIIIth Congress of the Pan Arab African Council of Ophthalmology (PAACO) and the XIIth UAE Ophthalmic Conference April **2005**, Dubai.
29. Combined Chemoreduction and Adjuvant Therapy to Control Retinoblastoma. **Naseripour M**, Bakhtiari P, Moghadam A, Vosough P, Nasrabadi M. International VIIIth Congress of the Pan Arab African Council of Ophthalmology (PAACO) and the XIIth UAE Ophthalmic Conference April **2005**, Dubai (P).
30. Optic Nerve Astrocytoma. **Naseripour** Bakhtiari P, Imani M, Sadeghipour. Ophthalmology (PAACO) and the XIIth UAE Ophthalmic Conference April **2005**, Dubai (P)
31. Do We Need Effective Modalities to Control the Patients with Advanced Retinoblastoma? **Naseripour M**, P. Bakhtiari, SH. Salimi, P Vosough. ISGED and IRS **2005** & ICOO **2005** Canada.
32. Regression of Advanced Retinoblastoma after Multiple Subconjunctival Carboplatin Injection. **Naseripour M**, N. Bahrivand, A. Vadipour, P. Bakhtiari. ISGED and IRS **2005** & ICOO **2005** Canada.
33. Plaque Radiotherapy in Vitrectomized Eye with Recurrent Retinoblastoma, **Naseripour M**, M Hashemi, R Jaber, M Almasi Nasrabadi. ISGED and IRS **2005** & ICOO **2005** Canada.
34. Transpupillary Thermotherapy (TTT) for Treatment of Idiopathic Choroidal Neovascularization(o). **Naseripour M**, Nikeghbali A, Ariaeetabar H, Bakhtiari P. 15th Iranian Congress of Ophthalmology. 15-18 December **2005** Tehran.

35. Brachytherapy Using Ruthenium-106 Plaque for Choroidal Management Methods (O). **Naseripour M**, Jaberi R, Bakhtiari P, Kheirkhah A, AliAkbar Navahi R. 15th Iranian Congress of Ophthalmology. 15-18 December **2005** Tehran
36. Case-Control Study of Occurrence of Predictors of Anterior Hyaloid Fibrovascular Proliferation after Diabetic Vitrectomy. Parvaresh MM, **Naseripour M**, Bakhtiari P, Khodadoust A. 15th Iranian Congress of Ophthalmology 15-18 December **2005** Tehran
37. Intravitreal Triamcinolone Injection for Treatment of Macular Edema Due to BRVO (O). Hashemi M, Parvaresh MM, **Naseripour M**, Manshai K. 15th Iranian Congress of Ophthalmology. 15-18 December **2005** Tehran
38. Intravitreal Triamcinolone Injection for the Treatment of Macular Edema due to CRVO (O). Hashemi M, Parvaresh MM, **Naseripour M**, Manshai K. 15th Iranian Congress of Ophthalmology 15-18 December **2005** Tehran
39. Intravitreal Triamcinolone Injection for CSME as Primary Treatment (O). Hashemi M, Parvaresh MM, **Naseripour M**, Manshai K. 15th Iranian Congress of Ophthalmology 15-18 December **2005** Tehran.
40. Transpupillary Thermotherapy (TTT) for Treatment of Choroidal Neovascularization due to Myopia (P). **Naseripour M**, Hashemi M, Ariaeetabar H, Bakhtiari P. 15th Iranian Congress of Ophthalmology 15-18 December **2005** Tehran
41. Transpupillary Thermotherapy (TTT) for Treatment of Occult, Classic and Mixed-Type Choroidal Neovascularization (CNV) in Age Related Macular Degeneration (ARMD) (O). **Naseripour M**, Parvaresh MM, Bakhtiari P, Manshai K, Salimi SH. 15th Iranian Congress of Ophthalmology 15-18 December **2005** Tehran
42. Transpupillary Thermotherapy (TTT) as primary Treatment or Adjuvant to plaque Radiotherapy for Choroidal Malignant Melanoma (O). **Naseripour M**, Parvaresh MM, Ariaeetabar H, Bakhtiari P. 15th Iranian Congress of Ophthalmology 15-18 December **2005** Tehran.
43. Do We Need More Effective Modalities to Control the Patients with Advanced Retinoblastoma? (O) . **Naseripour M**, Bakhtiari P, ZareMoghadam A, Salimi SH, Vosough P. 15th Iranian Congress of Ophthalmology 15-18 December **2005** Tehran.
44. Nerve Fiber Layer (NFL) and Macular Thickness Measurement by Optical Coherence Tomography (OCT) in Emmetropic, High Myopic and High Hyperopic Eyes Parvaresh MM, Imani M, **Naseripour M**, Bakhtiari P, Salimi SH. 15th Iranian Congress of Ophthalmology 15-18 December **2005** Tehran.
45. Ten years Survival Rate Study of Patients with Retinoblastoma in Iran. **Naseripour M**, P Vosough, F Arian, P Bakhtiari, SH Salimi. Saudi Ophthalmology Congress March **2006**.
46. Case - Control Study of Occurrence of Predictors of Anterior Hyaloid Fibrovascular Proliferation **Naseripour M**, M Parvaresh, P Bakhtiari, A Khodadoust. Saudi Ophthalmology Congress March **2006**.

47. Brachytherapy Using Ruthenium -106 Plaque for Choroidal Melanoma. **Naseripour M**, R Jaber, P Bakhtiari, A Kheirkhah, S Ali. Saudi Ophthalmology Congress March **2006**.
48. Optical Coherence Tomography (OCT) in Emmetropic, High-Myopic and High-Hyperopic Eyes. **Naseripour M**, M Parvaresh, P Bakhtiari, M Imani, A Kheirkhah. Saudi Ophthalmology Congress March **2006**.
49. Plaque Brachytherapy in Uveal Melanoma. Ramin Jabari, Naseripour M, Farhad Samiei The 3 th National Scientific Congress of IRSA 2005. 51. The role of hyperthermia in control of subfoveal CNV: stabilization of CNV with low recurrent rate. **Naseripour M**, Pejman Bakhtiari, XVI Ophthalmology Congress of Iran, November **2006**.
50. Evaluation of periocular carboplatin injection combined with chemotherapy for advanced intraocular retinoblastoma. **Naseripour M**, Akbarzadeh S, Bakhtiari P, Vosough P, Vadipour A XVI Ophthalmology Congress of Iran, November **2006**.
51. Efficacy of the Intravitreal Injection of Bevacizumab (Avastin) For Treatment of Wet – Type ARMD. **Naseripour M**, Ansari MR, Modarres Zadeh M, Bakhtiari P, Salimi Sh. XVI Ophthalmology Congress of Iran. November **2006**.
52. Plaque Radiotherapy for ocular surface tumors. **Naseripour M**, Ansari MR, Jaber, R, Bakhtiari P, Salimi Sh. XVI Ophthalmology Congress of Iran November **2006**.
53. Ten Years Survival Rate Study of Patients with Retinoblastoma In Iran. **Naseripour M**, Vosough P, Arian F, Bakhtiari P, Salimi SH. XVI Ophthalmology Congress of Iran, November **2006**.
54. The effect of transpupillary thermotherapy with or without Sub – Tenon triamcinolone injection for the treatment of CNV due to ARMD. **Naseripour M**, Vadipour A, Parvaresh MM, Bakhtiari P, Salimi Sh. XVI Ophthalmology Congress of Iran, November **2006**.
55. High dose versus low dose ruthenium 106 plaque radiotherapy for retinal vasoproliferative tumors (VPT). **Naseripour M**, Bakhtiari P, Jaber, R. ISOO MEETING 2007, International Society of Ocular Oncology, Siena, 26-30 June **2007**.
56. The prognosis of retinoblastoma in terms of patient's survival and globe survival. **Naseripour M**, Bakhtiari P., Ansari M.R., Vosough P. ISOO MEETING 2007, International Society of Ocular Oncology, Siena, 26-30 June **2007**.
57. Retinoblastoma: Predictor factors for patients survival. **Naseripour M**, Bakhtiari P., Vosough P., Arian F. ISOO MEETING 2007, International Society of Ocular Oncology, Siena, 26-30 June **2007**.
58. Ruthenium 106 plaque radiotherapy for choroidal malignant melanoma: 5 years' experience. **Naseripour M**, Nazari H, Bakhtiari P, Jaber, R. ISOO MEETING 2007, International Society of Ocular Oncology, Siena, 26-30 June **2007**.

59. Visual and anatomical results of brachytherapy in circumscribed choroidal hemangioma. **Naseripour M**, Bakhtiari P, Nazari H, Jaber R. ISOO MEETING 2007, International Society of Ocular Oncology, Siena, 26-30 June **2007**.
60. High Dose versus Low Dose Ruthenium 106 Plaque Radiotherapy for Retinal Vasoproliferative Tumors. **Naseripour M**, Bakhtiari P, Nazari H, Jaber R. 17th Iranian Congress of Ophthalmology, Tehran, 4-7 December **2007**.
61. Intravitreal Injection of Bevasizumb before Vitrectomy for Proliferative Diabetic Retinopathy. Modarres Zadeh M, **Naseripour M**, 17th Iranian Congress of Ophthalmology. Tehran, 4-7 December **2007**.
62. Ruthenium 106 Plaque Radiotherapy for Choroidal Malignant Melanoma: 5 Years Experiences. **Naseripour M**, Bakhtiari P, Jaber R. 17th Iranian Congress of Ophthalmology. Tehran, 4-7 December **2007**.
63. Intravitreal Injection of Bevacizumab for Treatment of Macular Edema after Retinal Vein Occlusion. **Naseripour M**, Modarres Zadeh M, Ansari MR, Falavarjani KG. Middle East African council of ophthalmology. UAE, Dubai. April-March **2007**.
64. Ruthenium-106 Plaque Radiotherapy for Choroidal Malignant Melanoma: 5 Years Experiences; **Naseripour M**, Nazari H, Bakhtiari P, Jaber R. 4th Asian Congress of Safe Communities. Thailand, 21-24 November **2007**.
65. **Naseripour M**, Bevacizumab and Retinal Ischemia. Annual meeting of Retina society. Iran, Zibakenar, 15 May **2008**
66. **Naseripour M**, 11th Annual Optometry Congress, Sep **2007** Tehran, Iran.
67. **Naseripour M**, Current and New pharmacologic treatments of ARMD Retina and Vitreous Seminar, June **2006** Tehran, Iran.
68. Sarcoidosis presenting as a choroidal tumor. Auther (s) Nazari H. **Naseripour M**, (Posters) XVIII Ophthalmology Congress of IRAN. 25-27 Nov **2008**.
69. Anti angiogenic therapy with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity (APROP) unresponsive to conventional laser therapy. Nazari H, Parvaresh MM, Hashemi M, Modarres Zadeh M, **Naseripour M**, Nikeghbali A. (Free papers) XVIII Ophthalmology Congress of IRAN. 25-27 Nov **2008**.
70. **Naseripour M**, Visual function and predictor factors following brachytherapy for circumscribed choroidal hemangioma. (Free papers) XVIII Ophthalmology Congress of IRAN. 25-27 Nov **2008**.
71. **Naseripour M**, Intravitreal use of bevacizumab (avastin) for choroidal neovascularization associated with age related macular degeneration; a full field ERG study. (Free papers). XVIII Ophthalmology Congress of IRAN. 25-27 Nov **2008**.

72. **Naseripour M**, Photodynamic therapy in retinal angiomas proliferations. (Free papers). XVIII Ophthalmology Congress of IRAN. 25-27 Nov **2008**.
73. **Naseripour M**, Primary transpupillary thermotherapy for small choroidal melanoma. (Free papers). XVIII Ophthalmology Congress of IRAN. 25-27 Nov **2008**.
74. **Naseripour M**, Ruthenium brachytherapy for retinoblastoma. (Free papers). XVIII Ophthalmology Congress of IRAN. 25-27 Nov **2008**.
75. **Naseripour M**, When to continue or to discontinue Avastin in exudative ARMD. Naseripour M. 6-8 March **2009**, Tehran Razi Convention Center.
76. **Naseripour M**, Pharmacotherapy for retinal capillary hemangioma, vasoproliferative tumors and coat` disease. 6-8 March **2009**, Tehran Razi Convention Center.
77. **Naseripour M**, When to continue or to discontinue Avastin in exudative ARMD. 6-8 March. **2009**, Tehran Razi Convention Center.
78. **Naseripour M**, Pharmacotherapy for retinal capillary hemangioma, vasoproliferative tumors and coat` disease. 6-8 March **2009**, Tehran Razi Convention Center.
79. **Naseripour M**, Ocular tumor management & it`s complication. 12th Iranian Congress of Optometry. 18-20 August **2009**. Tehran Razi Convention Center.
80. **Naseripour M**, Uveal melanoma management: Lessons from cytogenetic profiling. 3rd annual meeting of Iranian Retina Society. 22 Apr **2010**. Shiraz.
81. **Naseripour M**, Update on retinal disease and glaucoma: Panel discussion. 16th annual meeting of TUMS Eye Research center 5-7 May **2010**, Tehran.
82. **Naseripour M**, The Role of cataract surgery in macular disease. 4th annual meeting of IUMS Eye Research center, 21-23 July **2010** Tehran.
83. **Naseripour M**, Approach to a fundus mass. ghasenmi F XXAnnual Congress of the Iran society of Ophthalmology 11-8 Dec **2010**
84. **دکتر مسعود ناصری پور**- اتوفلورسانس فوندوس در بیماری استحاله وابسته به سن شبکیه سمینار یکروزه زجاجیه و شبکیه (1) مورخه 19/12/89
85. **Naseripour M**, Retinoblastoma Survival in Iran. SIOP Asia 2010, 3-5 March **2010** Kish Island.
86. **Naseripour M**, Surgical approach in Retinoblastoma. 6th Congress of the SIOP Asia. March 3-5 **2010**, Iran-Kish Island.
87. Ravindranath Y, **Naseripour M**, Epelman S, Vossough P. 6th Congress of the SIOP Asia. March 3-5 **2010**, Iran-Kish Island.
88. **Naseripour M**, Workshop: Approach to a fundus mass. XX Annual Congress of the Iranian Society of ophthalmology Nov.29- Dec.2, **2010**.

89. **Naseripour M**, Differential diagnosis of an amelanotic fundus mass. XX Annual Congress of the Iranian Society of ophthalmology Nov.29- Dec.2, **2010**.
90. **Naseripour M**, Approach to a fundus mass. XX Annual Congress of the Iranian Society of ophthalmology Nov.29- Dec.2, **2010**.
91. **Naseripour M**, Updates on management of AMD. XX Annual Congress of the Iranian Society of ophthalmology Nov.29- Dec.2, **2010**.
92. **Naseripour M**, Salvage Ru-106 Plaque Radiotherapy after failed primary chemotherapy for advanced Retinoblastoma. XX Annual Congress of the Iranian Society of ophthalmology Nov.29- Dec.2, **2010**.
93. **Naseripour M**, Trends in survival of Retinoblastoma patients in an ocular oncology unit in iran: 1991-2010. XX Annual Congress of the Iranian Society of ophthalmology Nov.29- Dec.2, **2010**.
94. **Naseripour M**, Controversies in vitreoretinal surgical techniques. (To Peel LIM? / Pros / Cons). XX Annual Congress of the Iranian Society of ophthalmology Nov.29- Dec.2, **2010**.
95. **Naseripour M**, Approach to a fundus mass. XX Annual Congress of the Iranian Society of ophthalmology Nov.29- Dec.2, **2010**.
96. **Naseripour M**, Approach to a fundus mass. XX Annual Congress of the Iranian Society of ophthalmology Nov.29- Dec.2, **2010**.
97. جراحی کاتاراکت باعث تشدید بیماریهای ماکولا DME , ARMD می شود ؟ دکتر مسعود ناصری پور – دکتر کارخانه – دکتر هاشمی – دکتر رمضانی . Controversies in ophthalmology 21-23 july . **2010**
98. EYELID. Demerci H, **Naseripour M**. Biannual Meeting ISOO **2011**, 14-17 November.
99. Mystery case. **Naseripour M**, International society of ocular oncology, Biannual Meeting ISOO **2011**, 14-17 November.
100. β -Radiation brachytherapy for large choroidal melanoma: Do we need A high dose to the apex? **Naseripour M**, falavarjani KG, Jaberi R, Irani AR, Azma Z. International society of ocular oncology, Biannual Meeting ISOO **2011**, 14-17 November.
101. Multidisciplinary coordinated services: what we need to improve in the management of RB. **Naseripour M**, Nazari H, Falavarjani KG, Soudi R, Maleki A, Ansari S. International society of ocular oncology, Biannual Meeting ISOO **2011**, 14-17 November
102. **Naseripour M**, Central serous chorioretinopathy. Controversies in ophthalmology 20-22 July **2011**

103. **Naseripour M**, Results of the Comparison of AMD Treatment Trials (CATT Study). Shahid Beheshti University of Medical Sciences. February 1-3, **2012**
104. Moderator of Oncology session in WOC. Hind Alkatan, Santosh Honavar, **Naseripour M**, Jacob pe'er, Jerry Shields. 12th MEACO International Congress.16-20 February **2012**, Abu Dhabi, United Arab Emirates.
105. **Naseripour M**, Miscellaneous Tumors / Photodynamic therapy (PDT): is it an effective treatment modality for retinal and choroidal vascular Tumors? .12th MEACO International Congress.16-20 February **2012**, Abu Dhabi, United Arab Emirates.
106. **Naseripour M**, Jerry Slieds, Naseripour M. Rapid Fire papers: chairpersons. 12th MEACO International Congress.16-20 February **2012**, Abu Dhabi, United Arab Emirates.
107. **Naseripour M**, Rapid Fire papers: Mystery Case. Naseripour M. 12th MEACO International Congress.16-20 February **2012**, Abu Dhabi, United Arab Emirates.
108. **Naseripour M**, Vitreoretinal considerations in cataract surgery. (Vitreoretinal interface changes after cataract surgery (OCT Findings)). Naseripour M. 18th Annual Farabi Seminar, Corneal transplantation and cataract, Mazandaran, Iran, **2012**.
109. **Naseripour M**, Ocular pathology & tumors 3. Uveal Nevus. APAO/SOE Busan 2012, 13-16 April **2012**. Bexco, Busan, Korea.
110. **Naseripour M**, Invited lecturer by Visual Sciences groups. Chaharshanbe-Soori Injuries Forum. 18th Annual Farabi Seminar, **2012**
111. **Naseripour M**, Nine Novel RBI Mutation and Genotype/ Phenotype Correlation in Patients with Retinoblastoma Referred to Rasoul Akram Hospital. 18th Annual Farabi Seminar, **2012**
112. **Naseripour M**, Update in Retinoblastoma. Zibknar, Rasht, **2012**
113. **Naseripour M**, How far do you continue the treatment in exudative ARMD? Controversies in ophthalmology. Eye Research Center, Rasoul Akram Hospital, Tehran University of Medical Sciences. 11-13 July **2012**.
114. **Naseripour M**, Symposium: Retina Disease (Part1), (Results of the comparison of AMD Treatment Trials (CATT Study)): Naseripour M . Advances and innovations in ophthalmology. 7th Annual Meeting of the Ophthalmic Research Center. Shahid beheshti University of Medical Sciences. February 1-3, **2012**.
115. **Naseripour M**, Vitreoretinal considerations in cataract surgery. (Vitreoretinal interface changes after cataract surgery (OCT Findings)). Masood Naseripour. 18th Annual Farabi Seminar, Corneal transplantation and cataract, Mazandaran, Iran, **2012**.
116. **Naseripour M**, Live surgery Performed in XXII Annual Congress Of The Iranian Society Of Ophthalmology ,30 Oct **2012**.

117. **Naseripour M**, Free Papers:Posterior Segment, Moderated in XXII Annual Congress Of The Iranian Society Of Ophthalmology ,31Oct **2012**.
118. **Naseripour M**, Temporary Keratoprosthesis: TPK,K-pro. Video Presented in posterior Segment Trauma Workshop in XXII Annual Congress Of The Iranian Society Of Ophthalmology ,1 Nov **2012**.
119. **Naseripour M**, Genotype – Phenotype Correlation in Iranian Patients with Retinoblastoma, Oral Presentation in XXII Annual Congress of the Iranian Society of Ophthalmology ,1 Nov **2012**.
120. **Naseripour M**, The Trend in the Survival of the Patient with Retinoblastoma, Poster Presentation in XXII Annual Congress Of The Iranian Society Of Ophthalmology ,1 Nov **2012**.
121. **Naseripour M**, The Chair of Free Paper, IRAVO Congress, 7march **2013**
122. **Naseripour M**, Genotype-Phenotype Correlation in Iranian Patients with Retinoblastoma,Oral Presentation in IRAVO Congress, 8 March **2013**
123. **دکتر مسعود ناصری پور**. رویکرد به ضایعات پیگمانته فوندوس. ارائه در برنامه فوق تخصصی گروه رتین: رویکرد به بیماریهای ویتره و رتین. نوزدهمین سمینار سالیانه فارابی و ششمین گردهمایی گروه فوق تخصصی ویترو و رتین انجمن چشم پزشکی ایران، تهران، هتل المپیک، 5 اردیبهشت 1392. **نوزدهمین سمینار سالیانه فارابی**
124. **دکتر مسعود ناصری پور**. اندوفتالمیت پس از جراحی کاتاراکت. ارائه در سمپوزیوم: اندوفتالمیت پس از جراحی کاتاراکت. نوزدهمین سمینار سالیانه فارابی و ششمین گردهمایی گروه فوق تخصصی ویترو و رتین انجمن چشم پزشکی ایران، تهران، هتل المپیک، 6 اردیبهشت 1392. **نوزدهمین سمینار سالیانه فارابی**
125. **Naseripour M**, Workshop: Approach to Intraocular Tumors. Moderated in 23th Annual Congress of the Iranian Society of Ophthalmology. Tuesday, 29 October, **2013**.
126. **Naseripour M**, Workshop: Approach to Intraocular Tumors. Approach to Pigmented Intraocular Tumors. Presented in 23th Annual Congress of the Iranian Society of Ophthalmology. Tuesday, 29 October, **2013**.
127. **Naseripour M**, Workshop: Approach to Intraocular Tumors. Presented in 23th Annual Congress of the Iranian Society of Ophthalmology. Tuesday, 29 October, **2013**
128. **دکتر مسعود ناصری پور**، تومورهای چشمی شایع در کودکان. ارائه شده در ششمین همایش سالیانه چشم پزشکی دانشگاه علوم پزشکی زاهدان. پنجشنبه 8 اسفند 1392، زاهدان.
129. **دکتر مسعود ناصری پور**، درمان تومورهای چشمی در کودکان. ارائه شده در ششمین همایش سالیانه چشم پزشکی دانشگاه علوم پزشکی زاهدان. پنجشنبه 8 اسفند 1392، زاهدان. **challenging case in exotropia**. ارائه شده در ششمین همایش سالیانه چشم پزشکی دانشگاه علوم پزشکی زاهدان
130. **Naseripour M**, Invited Speaker, Indications and Limitations of Fundus Imaging Techniques, Ultrasonography, Presented in WOC **2014**, 4 April, Tokyo.
131. **Naseripour M**, Invited Speaker, The Role of TTT, PDT and Anti VEG-F Treatment in Uveal Melanoma, Presented in WOC **2014**, 4 April, Tokyo

132. **Naseripour M**, Retina Subspecialty Day, New Concepts in Vitreoretinal Surgeries, Moderated in XXIV Annual Congress of the Iranian Society of Ophthalmology, Monday, December 01, **2014**, Razi Convention Center, Tehran.
133. **Naseripour M**, Keynote Lecture. Moderated in XXIV Annual Congress of the Iranian Society of Ophthalmology, Thursday, December 04, **2014**, Razi Convention Center, Tehran.
134. **Naseripour M**, Lunch Meeting: Ophthalmology Residency Training in Europe, USA, IRAN. Panel Discussion. Moderated in XXIV Annual Congress of the Iranian Society of Ophthalmology, Thursday, December 04, **2014**, Razi Convention Center, Tehran.
135. **Naseripour M**, Workshop: Ocular Oncology. Moderated in XXIV Annual Congress of the Iranian Society of Ophthalmology, Thursday, December 04, **2014**, Razi Convention Center, Tehran.
136. **Naseripour M**, Moderator of Free Paper 7 in 5th IRAVO Seminar, 6 March **2015**, Razi Convention Center, Tehran.
137. **Naseripour M**, Pediatric Ocular trauma 21th Farabi Annual Meeting, 6-8 May **2015** Olympic Hotel, Tehran, Iran.
138. **Naseripour M**, Retina Updates Symposium: Updates of intraocular melanoma. Presented in 10th Annual Seminar of Advances and Innovations in Ophthalmology, 29 January **2015**, Razi Convention Center, Tehran
139. **Naseripour M**, Workshop: Ocular Oncology, Melanoma and Pseudomelanoma. Presented in XXIV Annual Congress of the Iranian Society of Ophthalmology, Thursday, December 04, **2014**, Razi Convention Center, Tehran.
140. **Naseripour M**, Workshop: Ocular Oncology, Case Presentation. Presented in XXIV Annual Congress of the Iranian Society of Ophthalmology, Thursday, December 04, **2014**, Razi Convention Center, Tehran.
141. **Naseripour M**, Workshop of Approach to Open Globe Injury, Case Presentation. Presented in 20th Farabi Annual Meeting, 30 April- 2 May 2014 Olympic Hotel, Tehran, Iran.
142. **Naseripour M**, Management of a Fundus Mass in Elderly: Follow Up versus Intervention. 9th contraversis in ophthalmology, July **2015** 29-31. (Moderator)
143. **Naseripour M**. Updates of diabetic retinopathy. 8th vitreoretinal subspecialty day, Isfahan April **2015**
144. **Naseripour M**. AMD. 8th vitreoretinal subspecialty day, Isfahan April **2015**

145. **دکتر مسعود ناصري پور**. درمان جراحی در تومورهاي ملتحمه. تازه هاي تومورهاي ملتحمه و ضمايم
بیمارستان فارابی 5/6/94

146. **Naseripour M**, Retina Subspecialty day. Updates on Genetic Studies in Ocular Tumors. XXIV Annual Congress of the Iranian Society of Ophthalmology, Monday, December 14, **2015**, Razi Convention Center, Tehran.
147. **Naseripour M**, Fariba Ghasemi, Ahad Sedaghat. Workshop: Fundus Mass: What to do? XXIV Annual Congress of the Iranian Society of Ophthalmology, Thursday, December 17, **2015**, Razi Convention Center, Tehran.
148. **Naseripour M**, *Invited Speaker, Tips and Tricks in A&B Ultrasound in Diagnosis and Management of Intraocular Tumors*, World Ophthalmology Congress 2016 (WOC2016), February 5-9, **2016**, Guadalajara, Mexico
149. **Naseripour M**, *Invited Speaker, Peripapillary Cavemous Hemangioma*, World Ophthalmology Congress (WOC2016), February 5-9, **2016**, Guadalajara, Mexico
150. **Naseripour M**, Ophthalmology Updates 27-29 April 2016, Farabi Annual Meeting. Current State of Therapeutic Strategies in Age Related Macular Degeneration(AMD) Panel Discussion, Panel Discussion, Interactive Case Presentation, April 27, **2016**, 09:00 - 10:00
151. **Naseripour M**, Ophthalmology Updates 27-29 April 2016, Farabi Annual Meeting . Workshop: Case Presentations of Ocular Trauma, April 29, **2016**, 11:00 - 13:00
152. **Naseripour M**. Vitreoretinal interface abnormality symposium: Pneumatic and pharmacologic vitreolysis, April 21, **2016**, Kermanshah
153. **Naseripour M**, Workshop: Update on retinal degenerations. First spring ophthalmology meeting 11-14 April **2017**
154. **Naseripour M**, Workshop: controversies in approach to a fundus mass. First spring ophthalmology meeting 11-14 April **2017**
155. **Naseripour M**, Panel Discussion: Controversies in approach to treatment of ARMD. First spring ophthalmology meeting 11-14 April **2017**
156. **Naseripour M**, Panel Discussion: Controversies in approach to fundus mass. 12 Apr 2017. First spring ophthalmology meeting 11-14 April **2017**
157. **Naseripour M**, Workshop: neurodegenerative changes in DR. First spring ophthalmology meeting 11-14 April **2017**
158. **Naseripour M**, Workshop: Challenging Cases of Ocular Trauma and Emergency. Farabi Annual Meeting. Ophthalmology updates 26-8 April **2017**.
159. **Naseripour M**, Workshop: diabetic retinopathy: interactive case presentation and panel discussion 9:15-10:30. Farabi Annual Meeting. Ophthalmology updates 26-8 April **2017**.
160. **Naseripour M**, Speaker: Choroidal Metastasis: Incidence, Clinical Features and Management. West Asia Cancer Conference Scientific Agenda. 1 Dec. **2017**

161. **Naseripour M**, Speaker: Primary Versus Secondary Intraocular Tumors. XXVII Annual Congress of the Iranian Society of Ophthalmology. 4-7 Dec **2017**
162. **Naseripour M**, Case Presentation: 17:46 - 18:00 7 Dec. XXVII Annual Congress of the Iranian Society of Ophthalmology. 4-7 Dec **2017**
163. **Naseripour M**, Speaker: Updates on Retinal Imaging. 11:30 - 12:30 4 Dec. XXVII Annual Congress of the Iranian Society of Ophthalmology. 4-7 Dec **2017**
164. **Naseripour M**, Speaker: 2017 Young Ophthalmologist Programs , Retina. XXVII Annual Congress of the Iranian Society of Ophthalmology. 4-7 Dec **2017**.
165. **Naseripour M**, West Asia cancer conference (WACC) **2017- 9-11**
166. **Naseripour M**, Workshop: Tips and tricks in ocular Trauma and Emergency. Farabi Annual Meeting. Ophthalmology updates 2 May **2018**.
167. **Naseripour M**, Moderator: Ocular Tumors: Challenges and Controversies . Second spring ophthalmology meeting 18-20 April **2018**
168. **Naseripour M**, Speaker: Updates on Intraocular Tumor Imaging. XXVIII Annual congress of the Iranian society of ophthalmology 12-15 NOV **2018**
169. **Naseripour M**, Speaker: Rapid Fire Case Presentation. XXVIII Annual congress of the Iranian society of ophthalmology 12-15 NOV **2018**
170. **Naseripour M**, Speaker: Update on Retinovascular Disorders . XXVIII Annual congress of the Iranian society of ophthalmology 12-15 Nov **2018**
171. **Naseripour M**, Invited Speaker, Shams Festival on Ophthalmology and Visual Sciences, **2019**
172. Third Spring Ophthalmology Meeting. 17-19 April 2019 Razi convention center Tehran Iran. Panel Discussion: Controversies in Management of Masquerade Intra-Ocular Masses. Thursday 18 Apr **2019**.
173. **دکتر مسعود ناصری پور** – گرداننده - بیست و چهارمین سمینار سالیانه فارابی 16:00-17:30، چهارشنبه 12 اردیبهشت ماه 1397 – تهران، مرکز همایش‌های بین‌المللی پژوهشگاه صنعت نفت.
174. **دکتر مسعود ناصری پور** – گرداننده - یازدهمین سمینار سالیانه وینتره و ریتن سیزدهمین سمینار سالیانه گروه چشم دانشگاه علوم پزشکی جندی شاپور اهواز – 19 – 21 بهمن ماه 1397
175. **دکتر مسعود ناصری پور** – تازه های تصویر برداری تومور های داخل چشمی 8:40-9:10، پنجشنبه 1 آذر 97 – بیمارستان شهید بهشتی .
176. **دکتر مسعود ناصری پور** – فناوری سلول های بنیادی در درمان بیماری های چشمی - سومین سمپوزیوم پوست، ترمیم سلول های بنیادی و پزشکی بازساختی، 20 تیر 98 بیمارستان شهید مطهری

177. دکتر مسعود ناصری پور- معلم برتر در بیست و نهمین کنگره سالیانه انجمن چشم پزشکی ایران 28 آبان - 1 آذر 98 در مشهد

178. **Naseripour M**, Workshop: GCP (ICHE6-R2) for Investigators. 12 July **2019**.

179. **Naseripour M**, Keynote Lectures . XXIX Annual congress of the Iranian Society of Ophthalmology. 19-22 NOV **2019**.

180. **Naseripour M**, Speaker. Surgical Techniques in Subretinal Cell Therapy. XXIX Annual congress of the Iranian Society of Ophthalmology. 19-22 NOV **2019**.

181. **Naseripour M**, Moderator. Speaker. Iran award. Third, spring ophthalmology meeting. 17-19 April **2019** Razi convention center Tehran Iran.

182. **Naseripour M**, Speaker. Webinar. World Ophthalmology Congress **2020**. 30 September 2020.

183. **Naseripour M**, Speaker. Webinar, Application of Stem Cell and Tissue Engineering in the field of Ophthalmology, IRSO 16 July **2021**

184. **Naseripour M**, Moderator. Webinar, Iranian Retina Society with Collaboration of Ocular Oncology Service of IUMS held: "Uveal Melanoma: A to Z" Friday, 30th July 2021

185. **Naseripour M**, Speaker. Webinar, Challenging Cases in Retinal Diseases and Surgery XXXI Annual Congress of the Iranian Society of Ophthalmology Saturday 16 October **2021**

186. **Naseripour M**, Panelists. Webinar, Comprehensive review of macular OCT Khorasan Ophthalmological Association 20 January **2022**

186. **Naseripour M**, Speaker. Webinar, The Role of scleral buckling in modern ophthalmology 21 April **2022**

Useful Links

- https://isid.research.ac.ir/Masood_Naseripour
- <https://orcid.org/0000-0003-1217-3470>
- <https://scholar.google.com/citations?user=PpHPuaMAAAAJ&hl=en>
- <https://www.scopus.com/authid/detail.uri?authorId=18634711400>

1401/08/29

فرهمنند